Viewing nowCombinationDanumet Tablets 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
KS Pharma Co., Ltd.

MFDS item code 202300831 · Approved 2023.03.13 · Insurance code 059001190
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help patients with type 2 diabetes more effectively control their blood sugar levels while following dietary and exercise therapies. The two active ingredients, sitagliptin and metformin, work together to improve blood sugar levels and enhance the efficiency of blood sugar management. Therefore, it plays an important role in preventing complications of diabetes through consistent treatment and lifestyle improvements. For these reasons, it is very suitable for blood sugar control in type 2 diabetes patients and plays a crucial role in their health management.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Use This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Medicine).
This medication contains two active ingredients, each of which has different precautions to be aware of. First, one of the active ingredients, sitagliptin, can cause rare but serious allergic reactions. Such reactions may occur within 3 months after starting the medication, so if symptoms such as skin rash or difficulty breathing occur, you should stop taking the medication immediately and consult a doctor. Additionally, while taking sitagliptin, pancreatitis (inflammation of the pancreas) may occur, so if symptoms such as abdominal pain, vomiting, or fever arise, stop taking the medication immediately and inform your healthcare provider. Second, the other active ingredient, metformin, may pose risks to patients with impaired kidney function, severe infections, or dehydration. In particular, it should not be used in cases of significantly impaired kidney function. Metformin can cause lactic acidosis, a rare but life-threatening metabolic disorder, so if sudden symptoms such as difficulty breathing, muscle pain, fatigue, or abdominal pain occur, stop taking the medication immediately and seek emergency treatment. Also, this medication should be temporarily discontinued before diagnostic tests using specific contrast agents and resumed only after confirming normal kidney function post-examination. This medication is not to be administered to pregnant or breastfeeding women, nor to children under 18 years of age. During treatment, hypoglycemia may occur, so particularly if taken with other blood glucose-lowering agents, blood sugar levels should be monitored frequently, and patients should be aware of hypoglycemic symptoms. Furthermore, excessive alcohol consumption, intense exercise, and irregular meals may increase the risk of hypoglycemia or lactic acidosis, so precautions should be taken. Regular monitoring of kidney function and blood tests, including Vitamin B12 levels, is recommended while taking this medication. Finally, this medication contains specific coloring agents, and patients allergic to these components should be cautious.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is best to store it at room temperature between 1 and 30 degrees Celsius. Proper storage helps to maintain the effectiveness of the medication for a longer period.
Pink oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
KS Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.